Carlos Rogério Figueiredo

From Wikitia
Jump to navigation Jump to search
Carlos Rogério Figueiredo
Add a Photo
NationalityBrazilian
Alma materFederal University of São Paulo, Brazil
Occupation
  • Immunologist
  • Cancer Researcher
  • Adjunct Professor

Carlos Rogerio Figueiredo

Carlos Rogério Figueiredo is a Brazilian/Portuguese immunologist, cancer researcher and Adjunct Professor at the University of Turku, in Finland. Figueiredo's research focuses on cancer immunobiology, immunotherapy, cancer cell biology and cancer prognostication, with particular interests in melanomas, lung and breast cancers. As an Academy of Finland Research Fellow, Figueiredo established the Medical Immuno-Oncology Research Group (MIORG) at the Faculty of Medicine, as part of the Institute of Biomedicine in the University of Turku. MIORG is a multidisciplinary immuno-oncology research group that aims to advance immunotherapy development and cancer prognostication.

Education

Figueiredo completed his Ph.D. in Immunology and Microbiology under the guidance of Professor Luiz R. Travassos at the Federal University of São Paulo, Brazil. Professor Travassos was also a tenured Professor at the Memorial Sloan Kettering Cancer Center|Memorial Sloan Kattering Cancer Center together with the his collaborator and friend, Professor Lloyd J. Old, considered the Father of Modern Tumor Immunology[1]. Travassos introduced Figueiredo to immunochemistry and cancer immunobiology during his Ph.D. studies in Brazil, which shaped his future research and teaching. Figueiredo's research led to the discovery of new antitumor drugs, such as small peptides derived from immunoglobulins and monoclonal antibodies with antitumor functions against advanced metastatic tumors[2]. During his postdoctoral studies at the University of Liverpool, Figueiredo furthered his understanding of the mechanisms behind antitumor immunotherapies he had developed and fostered collaboration in combinatorial drug development[3][4][5]. In a subsequent postdoctoral period, Figueiredo gained advanced training in precision cancer pathology under the mentorship of Professor Sarah E. Coupland. His training focused on interpreting immune infiltrates in tumor biopsies from cancer patients, including ocular melanomas and tumors that develop metastases in the liver. While training in Liverpool, Figueiredo received funding from the North West Cancer Research to conduct reverse translational clinical research, primarily centered on applying single-cell mass cytometry and spatial NanoString GeoMX to immune profiling of metastatic ocular melanomas resistant to immune checkpoint therapies. In Finland, Figueiredo worked as a postdoc at the MediCity research laboratory at the University of Turku, and was later awarded a docentship in immunology by the same Institution.

Research

Figueiredo has been actively involved in research and collaboration, obtaining funding from various organizations both as a principal investigator (PI) and as a co-investigator (Co-I). Recent funding includes the Academy of Finland Fellowship (2020-2025) for prognostication and drug development related to immune checkpoint therapies, support from the Jane and Aatos Erkko Foundation for the discovery and characterization of biomarkers of resistance to immunotherapies, and resources from the Sigrid Juselius Foundation for the investigation of repurposed drugs that counteract the immunosuppressive tumor microenvironment. In total, Figueiredo has received over €1.5 million as a principal investigator and more than €20 million as a co-investigator.

Publications

Figueiredo is an author of more than 50 articles published in international peer-reviewed scientific journals, with over 1500 citations and an early-career H-index of 23, according to Google Scholar[6]. Highly cited papers include the discovery of factors contributing to immunotherapy resistance, such as the loss of BAP1 gene expression, which holds implications for therapy advancement[7], and the rational development of a therapeutic antitumor CDR-derived peptide which blocks an important mechanism of melanoma immune evasion[8]. Lately, his group has made significant progress in discovering novel biomarkers related to metabolic alterations in metastatic ocular melanomas. They have also developed new prognostic signatures for these changes and identified potential combination therapies to counteract these issues[9], and in dissecting alternative mechanism of immune checkpoint therapy resistance, such as the epigenetic suppression of NKT cell generation[10].

References

  1. ↑ "Lloyd J. Old, MD, Father of Modern Tumor Immunology, Dies at 78 of Prostate Cancer". Cancer Research Institute. Retrieved 2023-05-03.
  2. ↑ Figueiredo, Carlos R.; Matsuo, Alisson L.; Azevedo, Ricardo A.; Massaoka, Mariana H.; Girola, Natalia; Polonelli, Luciano; Travassos, Luiz R. (2015-09-22). "A novel microtubule de-stabilizing complementarity-determining region C36L1 peptide displays antitumor activity against melanoma in vitro and in vivo". Scientific Reports. 5 (1): 14310. doi:10.1038/srep14310. ISSN 2045-2322.
  3. ↑ Figueiredo, Carlos R.; Azevedo, Ricardo A.; Mousdell, Sasha; Resende-Lara, Pedro T.; Ireland, Lucy; Santos, Almudena; Girola, Natalia; Cunha, Rodrigo L. O. R.; Schmid, Michael C.; Polonelli, Luciano; Travassos, Luiz R.; Mielgo, Ainhoa (2018). "Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma". Frontiers in Immunology. 9: 1132. doi:10.3389/fimmu.2018.01132. ISSN 1664-3224. PMC 5974174. PMID 29875777.
  4. ↑ Machado, Fabrício C.; Girola, Natália; Maia, Vera S. C.; Bergami-Santos, Patrícia C.; Morais, Alice S.; Azevedo, Ricardo A.; Figueiredo, Carlos R.; Barbuto, José A. M.; Travassos, Luiz R. (2019). "Immunomodulatory Protective Effects of Rb9 Cyclic-Peptide in a Metastatic Melanoma Setting and the Involvement of Dendritic Cells". Frontiers in Immunology. 10: 3122. doi:10.3389/fimmu.2019.03122. ISSN 1664-3224. PMC 6974543. PMID 32010152.
  5. ↑ Ireland, Lucy; Santos, Almudena; Campbell, Fiona; Figueiredo, Carlos; Hammond, Dean; Ellies, Lesley G.; Weyer-Czernilofsky, Ulrike; Bogenrieder, Thomas; Schmid, Michael; Mielgo, Ainhoa (April 2018). "Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer". Oncogene. 37 (15): 2022–2036. doi:10.1038/s41388-017-0115-x. ISSN 1476-5594. PMC 5895608. PMID 29367764.
  6. ↑ "Carlos Rogério Figueiredo". scholar.google.com. Retrieved 2023-05-03.
  7. ↑ Figueiredo, Carlos R.; Kalirai, Helen; Sacco, Joseph J.; Azevedo, Ricardo A.; Duckworth, Andrew; Slupsky, Joseph R.; Coulson, Judy M.; Coupland, Sarah E. (April 2020). "Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development". The Journal of Pathology. 250 (4): 420–439. doi:10.1002/path.5384. ISSN 1096-9896. PMC 7216965. PMID 31960425.
  8. ↑ Figueiredo, Carlos R.; Azevedo, Ricardo A.; Mousdell, Sasha; Resende-Lara, Pedro T.; Ireland, Lucy; Santos, Almudena; Girola, Natalia; Cunha, Rodrigo L. O. R.; Schmid, Michael C.; Polonelli, Luciano; Travassos, Luiz R.; Mielgo, Ainhoa (2018). "Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma". Frontiers in Immunology. 9: 1132. doi:10.3389/fimmu.2018.01132. ISSN 1664-3224. PMC 5974174. PMID 29875777.
  9. ↑ Matareed, Maisoon; Maranou, Eleftheria; Koskela, Saara A.; Mehmood, Arfa; Kalirai, Helen; Coupland, Sarah E.; Figueiredo, Carlos R. (2023-02-24). "Novel prognostication biomarker adipophilin reveals a metabolic shift in uveal melanoma and new therapeutic opportunities". The Journal of Pathology. doi:10.1002/path.6076. ISSN 1096-9896. PMID 36825655.
  10. ↑ Wang, Mona Meng; Koskela, Saara A.; Mehmood, Arfa; Langguth, Miriam; Maranou, Eleftheria; Figueiredo, Carlos R. (2023). "Epigenetic control of CD1D expression as a mechanism of resistance to immune checkpoint therapy in poorly immunogenic melanomas". Frontiers in Immunology. 14: 1152228. doi:10.3389/fimmu.2023.1152228. ISSN 1664-3224.

External links

Add External links

This article "Carlos Rogério Figueiredo" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.

Retrieved from "https://wikitia.com/index.php?title=Carlos_Rogério_Figueiredo&oldid=177375"